Objective:

To advocate for the exclusion of eyewear and optical products from new tariff actions linked to Section 301 investigations, specifically those related to structural excess capacity.

Key Findings:

• Eyewear is a demand-driven, medically necessary product, not a commodity subject to overproduction, and any tariff increases could jeopardize patient care.
• Additional duties on optical inputs would increase costs for US manufacturers and undermine competitiveness, potentially leading to reduced innovation.
• Higher tariffs could lead to delayed patient care, increasing risks of undetected conditions such as diabetic eye disease and glaucoma.
• Prescription eyewear is classified as a Class I medical device but lacks the same tariff exemptions as other low-risk medical products, which is a significant oversight.

Interpretation:

The proposed tariffs could negatively impact both the optical industry and patient access to necessary eyewear, highlighting the need for careful consideration of tariff policies.

Limitations:

• The testimony reflects the perspective of The Vision Council and may not encompass all viewpoints within the industry, which could lead to a narrow understanding of the issue.
• The hearings are ongoing, and final decisions on tariffs have yet to be made, leaving room for changes in the situation.

Conclusion:

The Vision Council urges the USTR to consider the unique nature of the optical industry and its reliance on global inputs to avoid adverse effects on affordability and public health.